Verified employee & interview reviews

Eris Lifesciences Reviews

Ahmedabad, Gujarat

4.0/ 5

3 reviews

Eris Lifesciences Limited is a leading publicly listed Indian pharmaceutical company focused primarily on the domestic branded formulations market. Established in 2007 and headquartered in Ahmedabad, Gujarat, it is recognized as one of the youngest companies to rank within the top 20 of the Indian Pharmaceutical Market (IPM). The company has carved out a distinct niche by maintaining a pure-play domestic formulations business model, steering clear of heavy reliance on acute segments or generic exports, and instead anchoring its growth in high-margin chronic and sub-chronic lifestyle-related therapies. The core business operations of Eris Lifesciences are structurally aligned with high-growth therapeutic areas, particularly cardiometabolic care, which includes substantial market shares in cardiology and anti-diabetes treatments. Additionally, the company has expanded its footprint into other prominent specialties such as gastroenterology, neurosciences, gynecology, and vitamins, minerals, and nutrients (VMN). In recent years, Eris has strategically diversified its portfolio into emerging fields like dermatology, medical aesthetics, nephrology, oncology, and the in-vitro fertilization (IVF) market through its dedicated division, Eris BioART. This diversification has been heavily accelerated by high-profile acquisitions, including the purchase of Oaknet Healthcare, the generic semaglutide partnership with Natco Pharma, and the acquisition of the domestic branded formulations business units of Biocon Biologics. Furthermore, its entry into the sterile injectables market was solidified through a controlling equity acquisition in Swiss Parenterals. Operationally, Eris Lifesciences relies on a vertically integrated structure supported by two WHO-GMP approved manufacturing facilities. Its primary facility is located in Guwahati, Assam, which handles a significant portion of its production, supplemented by a newer facility in Gujarat that reached full operational capability to deliver fiscal and production benefits. The company distributes its extensive portfolio of mother brands through a robust pan-India distribution network that features more than 4,000 stockists and services over 500,000 retail chemists. To drive prescriptions and brand loyalty, Eris deploys a sizable field force of over 3,400 medical representatives who engage directly with more than 80,000 specialists and super-specialist doctors. Financially, Eris Lifesciences is publicly traded on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Led by Founder, Chairman, and Managing Director Amit Bakshi, the company has consistently demonstrated strong financial metrics, reporting consolidated revenue from operations of approximately INR 2,910 crore for the fiscal year ended March 31, 2025. The company maintains an industry-leading average gross margin of around 82% and a resilient EBITDA margin profile. Following its aggressive acquisition strategy, the management has prioritized deleveraging its balance sheet, successfully reducing its Net Debt to EBITDA ratio. Beyond commercial manufacturing, Eris emphasizes patient care initiatives, pioneering large-scale digital interactions and deploying diagnostic monitoring technologies like ambulatory blood pressure and continuous glucose monitoring systems to improve national health outcomes.